Example: tourism industry
Auxiliary Medicinal Products in Clinical Trials
Auxiliary Medicinal Products in Clinical Trials 28 June 2017 6 2001/83/EC2”. Although this article does not distinguish between authorised and non-authorised AxMPs, Directive 2001/83/EC applies only to authorised medical products. In order to ensure supervision of the clinical trials and participants’ safety, the same
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
International Accounting Standard 39 Financial …
ec.europa.euEC staff consolidated version as of 18 February 2011 FOR INFORMATION PURPOSES ONLY 1 International Accounting Standard 39 Financial …
International Financial Reporting Standard 1
ec.europa.euEC staff consolidated version as of 21/06/2012, ²² EN – EU IFRS 1 FOR INFORMATION PURPOSES ONLY International Financial Reporting Standard 1
International Financial Reporting Standard 3 …
ec.europa.euEC staff consolidated version as of 18 February 2011 FOR INFORMATION PURPOSES ONLY 1 International Financial Reporting Standard 3 Business Combinations
Russia - Country Page - European Commission
ec.europa.euLast update: November 2017 1 Russia - Country Page 1. Available national programmes or funds that could provide support to Russian Horizon 2020 participants
Evaluation of Innovation Activities - European …
ec.europa.euJune 2012 Evaluation of Innovation Activities Guidance on methods and practices Evaluation of Innovation Activities Guidance on methods and practices
EN Horizon 2020 Work Programme 2018-2020
ec.europa.euHorizon 2020 - Work Programme 2018-2020 Health, demographic change and wellbeing Part 8 - Page 3 of 124 SC1-BHC-19-2019: Implementation research for maternal and child health..... 41
H2020 Programme - ec.europa.eu
ec.europa.eu5 Your policy should also: reflect the current state of consortium agreements on data management be consistent with exploitation and Intellectual Property Rights (IPR)
Literature review Teachers’ core ... - ec.europa.eu
ec.europa.eu© European Commission 1 EUROPEAN COMMISSION Directorate-General for Education and Culture Lifelong learning: policies and …
WP243 ANNEX - FREQUENTLY ASKED QUESTIONS …
ec.europa.euWP243 ANNEX - FREQUENTLY ASKED QUESTIONS The objective of this annex is to answer, in a simplified and easy-to-read format, some of the key questions that organisations may have regarding the new requirements under the GDPR to appoint a
Teachers’ continuing professional development
ec.europa.eu© European Commission 2 Literature review Quality in Teachers’ continuing professional developmenti 1. Teacher Professional Development: the …
Related documents
Management of Safety Information from Clinical Trials
cioms.chSafety Information from Clinical Trials Report of CIOMS Working Group VI Geneva 2005 CIOMS Management of Safety Information from Clinical Trials CIOMS publications may be obtained directly from CIOMS, c/o World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland or by e-mail to cioms@who.int
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.accessdata.fda.govBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of QULIPTA was evaluated in 1958 patients with migraine who received at ...
European Union Clinical Trials Information System CTIS: Go ...
www.ema.europa.euEuropean Union Clinical Trials Information System CTIS: Go-live Planning EMA/MB/473854/2021 Page 5/12 3. Public website – for the public to search and view publicly available data and information relating to clinical trials in the EU. In accordance with the CTR, the EUPD provides a single entry point for the submission of data and
Safety Reporting in Clinical Trials - Home | ClinRegs
clinregs.niaid.nih.govSafety Reporting • SAHPRA/CTC requires stringent reporting criteria and timelines. • Safety reporting should be defined by the Applicant in the protocol and CTF1. • Certain clinical trials may require special and exceptional adverse event monitoring and reporting that will be specified by SAHPRA on a protocol-specific basis.
Safety monitoring and reporting for clinical trials in Europe
www.ema.europa.euAnnual Safety Report – An annual summary of all serious adverse events for an active compound in clinical evaluation with a safety evaluation relating to the ongoing study (ies) – New upcoming format: DSUR. Update Investigator’s brochure (IB) – At least once per year according to Good Clinical Practice
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED ... - …
cdn.pfizer.compf-07302048 (bnt162 rna-based covid-19 vaccines) protocol c4591001 page 1 a phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to …